Intellectual property issues in genomics.

@article{citeulike:1781971, abstract = {Controversy over intellectual property rights in the results of large-scale cDNA sequencing raises intriguing questions about the roles of the public and private sectors in genomics research, and about who stands to benefit (and who stands to lose) from the private appropriation of genomic information. While the US Patent and Trademark Office has rejected patent applications on cDNA fragments of unknown function from the National Institutes of Health, private firms have pursued three distinct strategies for exploiting unpatented cDNA sequence information: exclusive licensing, non-exclusive licensing and dedication to the public domain.}, address = {University of Michigan Law School, Ann Arbor, MI 48109, USA. rse@umich.edu}, author = {Eisenberg, R. S. }, citeulike-article-id = {1781971}, doi = {10.1016/0167-7799(96)10040-8}, issn = {0167-7799}, journal = {Trends Biotechnol}, keywords = {commercialization, genetics-and-law, genomics, intellectual-property, legal}, month = {August}, number = {8}, pages = {302--307}, posted-at = {2007-10-18 01:39:33}, priority = {2}, title = {Intellectual property issues in genomics.}, url = {http://dx.doi.org/10.1016/0167-7799(96)10040-8}, volume = {14}, year = {1996} }

TY - JOUR ID - citeulike:1781971 L3 - citeulike-article-id:1781971 TI - Intellectual property issues in genomics. JF - Trends Biotechnol VL - 14 IS - 8 SP - 302 EP - 307 AD - University of Michigan Law School, Ann Arbor, MI 48109, USA. rse@umich.edu SN - 0167-7799 N2 - Controversy over intellectual property rights in the results of large-scale cDNA sequencing raises intriguing questions about the roles of the public and private sectors in genomics research, and about who stands to benefit (and who stands to lose) from the private appropriation of genomic information. While the US Patent and Trademark Office has rejected patent applications on cDNA fragments of unknown function from the National Institutes of Health, private firms have pursued three distinct strategies for exploiting unpatented cDNA sequence information: exclusive licensing, non-exclusive licensing and dedication to the public domain. KW - commercialization KW - genetics-and-law KW - genomics KW - intellectual-property KW - legal AU - Eisenberg, RS PY - 1996/08// UR - http://dx.doi.org/10.1016/0167-7799(96)10040-8 ER -